×

Mylan may have misclassified EpiPen under Medicaid: Report

12:28 PM ET Fri, 2 Sept 2016

According to Bloomberg, Mylan may have misclassified its EpiPen product under certain Medicaid guidelines. CNBC's Dominic Chu reports the details. John Spallanzani, GFI Group chief macro strategist, and the "FMHR" traders weigh in.